BAA revealed a significantly increasing bias of -3.3 + 10.7 mg/dL in people with diabetes receiving insulin therapy to -15.2 ± 13.6 mg/dL in people with ITT (p < 0.01).<h4>Conclusion</h4>CGM accuracy can vary in different clinical hypoglycaemia scenarios. The gene discussed is INS; the disease is diabetes mellitus.